Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
08
2020
accepted:
14
12
2020
entrez:
29
12
2020
pubmed:
30
12
2020
medline:
19
3
2021
Statut:
epublish
Résumé
HIV patients are at increased cardiovascular risk while available European cardiovascular recommendations are ambiguous. Retrospective analysis of 389 HIV-patients was conducted. Cardiovascular risk was determined by D:A:D, Framingham and SCORE scales. Patients were divided into risk groups as recommended by EACS 2019, PTN AIDS 2019 and ESC/EAS 2019 Guidelines and hypolipemic treatment was evaluated. In total, 389 HIV-positive patients took part in the study, most of whom were men (n = 312, 80.4%), mean age 41.69±10years. Mean lipid levels among all HIV patients: Tch:177.2±36mg/dl, HDL:48.9±18mg/dl, LDL:103.8±31mg/dl, TG:143.3±81mg/dl, AIP:0.45±0.3, non-HDL:129.2±36 mg/dl. Most of the participants (n = 360, 92.5%) were assigned to the high cardiovascular risk group according to ESC/EAS and PTN AIDS guidelines. The achievement of therapeutic LDLs according to ESC/EAS was 10.3% for those at very high cardiovascular risk (8.7% on lipid lowering treatment vs. 16.7% without hypolipemic drugs) and 12.0% (5.8% treated vs. 13.6% untreated) at high cardiovascular risk; according to PTN AIDS,17.2% achievement was noted by the very high-risk group (13% treated vs. 33.3% untreated), and 45.9% for the high-risk group (37.7% treated vs. 48.0% untreated); according to EACS Guidelines, 2.5% achievement in secondary prevention (3.8% treatedvs. 0% untreated) and 24.7% in primary prevention (22.2% treated vs. 26.1% untreated). Mean doses of statins were 8.75mg±6mg (Rosuvastatin) and 22.35±19mg (Atorvastatin). The achievement of therapeutic LDLs by all recommendations is unsatisfactory, and generally worse in patients on lipid lowering therapy. Hypolipemic treatment of our HIV patients is based on low doses of statins, even in secondary prevention.
Sections du résumé
BACKGROUND
HIV patients are at increased cardiovascular risk while available European cardiovascular recommendations are ambiguous.
METHODS
Retrospective analysis of 389 HIV-patients was conducted. Cardiovascular risk was determined by D:A:D, Framingham and SCORE scales. Patients were divided into risk groups as recommended by EACS 2019, PTN AIDS 2019 and ESC/EAS 2019 Guidelines and hypolipemic treatment was evaluated.
RESULTS
In total, 389 HIV-positive patients took part in the study, most of whom were men (n = 312, 80.4%), mean age 41.69±10years. Mean lipid levels among all HIV patients: Tch:177.2±36mg/dl, HDL:48.9±18mg/dl, LDL:103.8±31mg/dl, TG:143.3±81mg/dl, AIP:0.45±0.3, non-HDL:129.2±36 mg/dl. Most of the participants (n = 360, 92.5%) were assigned to the high cardiovascular risk group according to ESC/EAS and PTN AIDS guidelines. The achievement of therapeutic LDLs according to ESC/EAS was 10.3% for those at very high cardiovascular risk (8.7% on lipid lowering treatment vs. 16.7% without hypolipemic drugs) and 12.0% (5.8% treated vs. 13.6% untreated) at high cardiovascular risk; according to PTN AIDS,17.2% achievement was noted by the very high-risk group (13% treated vs. 33.3% untreated), and 45.9% for the high-risk group (37.7% treated vs. 48.0% untreated); according to EACS Guidelines, 2.5% achievement in secondary prevention (3.8% treatedvs. 0% untreated) and 24.7% in primary prevention (22.2% treated vs. 26.1% untreated). Mean doses of statins were 8.75mg±6mg (Rosuvastatin) and 22.35±19mg (Atorvastatin).
CONCLUSIONS
The achievement of therapeutic LDLs by all recommendations is unsatisfactory, and generally worse in patients on lipid lowering therapy. Hypolipemic treatment of our HIV patients is based on low doses of statins, even in secondary prevention.
Identifiants
pubmed: 33373417
doi: 10.1371/journal.pone.0244675
pii: PONE-D-20-27214
pmc: PMC7771861
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244675Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMJ. 2012 Jan 25;344:d8136
pubmed: 22279114
Postepy Hig Med Dosw (Online). 2011 Nov 25;65:770-83
pubmed: 22173442
Curr HIV/AIDS Rep. 2018 Jun;15(3):233-244
pubmed: 29752699
Eur J Prev Cardiol. 2016 Jan;23(2):214-23
pubmed: 25882821
Eur J Prev Cardiol. 2017 Aug;24(12):1297-1307
pubmed: 28578613
Circulation. 2018 May 22;137(21):2203-2214
pubmed: 29444987
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Lancet Public Health. 2017 Jan;2(1):e35-e46
pubmed: 29249478
Am Heart J. 2017 Jan;183:91-101
pubmed: 27979047
J Clin Lipidol. 2018 Jul - Aug;12(4):988-998.e5
pubmed: 29853312
PLoS One. 2019 Oct 11;14(10):e0223181
pubmed: 31603906
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501
pubmed: 20543702
Am Heart J. 2019 Jun;212:23-35
pubmed: 30928825
Am Heart J. 1991 Jan;121(1 Pt 2):293-8
pubmed: 1985385
Curr Vasc Pharmacol. 2016;14(3):280-7
pubmed: 26733388
Kardiol Pol. 2015;73(10):958-61
pubmed: 26521843
HIV Med. 2020 Oct 21;:
pubmed: 33084173
Int J Environ Res Public Health. 2019 Nov 30;16(23):
pubmed: 31801221
Circulation. 2019 Jul 9;140(2):e98-e124
pubmed: 31154814
JRSM Cardiovasc Dis. 2017 Nov 06;6:2048004017740478
pubmed: 29435266
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
HIV Med. 2020 Aug;21(7):418-428
pubmed: 32168418
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
Kardiol Pol. 2013;71(3):253-9
pubmed: 23575780
Med J Islam Repub Iran. 2015 Jul 25;29:240
pubmed: 26793631
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Am Coll Cardiol. 2020 May 26;75(20):2570-2584
pubmed: 32234462
J Infect Dis. 2012 Jun;205 Suppl 3:S375-82
pubmed: 22577211
Vnitr Lek. 2006 Jan;52(1):64-71
pubmed: 16526201